Back
About RSIS
Introduction
Building the Foundations
Welcome Message
Board of Governors
Staff Profiles
Executive Deputy Chairman’s Office
Dean’s Office
Management
Distinguished Fellows
Faculty and Research
Associate Research Fellows, Senior Analysts and Research Analysts
Visiting Fellows
Adjunct Fellows
Administrative Staff
Honours and Awards for RSIS Staff and Students
RSIS Endowment Fund
Endowed Professorships
Career Opportunities
Getting to RSIS
Research
Research Centres
Centre for Multilateralism Studies (CMS)
Centre for Non-Traditional Security Studies (NTS Centre)
Centre of Excellence for National Security
Institute of Defence and Strategic Studies (IDSS)
International Centre for Political Violence and Terrorism Research (ICPVTR)
Research Programmes
National Security Studies Programme (NSSP)
Social Cohesion Research Programme (SCRP)
Studies in Inter-Religious Relations in Plural Societies (SRP) Programme
Other Research
Future Issues and Technology Cluster
Research@RSIS
Science and Technology Studies Programme (STSP) (2017-2020)
Graduate Education
Graduate Programmes Office
Exchange Partners and Programmes
How to Apply
Financial Assistance
Meet the Admissions Team: Information Sessions and other events
RSIS Alumni
Outreach
Global Networks
About Global Networks
RSIS Alumni
Executive Education
About Executive Education
SRP Executive Programme
Terrorism Analyst Training Course (TATC)
International Programmes
About International Programmes
Asia-Pacific Programme for Senior Military Officers (APPSMO)
Asia-Pacific Programme for Senior National Security Officers (APPSNO)
International Conference on Cohesive Societies (ICCS)
International Strategy Forum-Asia (ISF-Asia)
Publications
RSIS Publications
Annual Reviews
Books
Bulletins and Newsletters
RSIS Commentary Series
Counter Terrorist Trends and Analyses
Commemorative / Event Reports
Future Issues
IDSS Papers
Interreligious Relations
Monographs
NTS Insight
Policy Reports
Working Papers
External Publications
Authored Books
Journal Articles
Edited Books
Chapters in Edited Books
Policy Reports
Working Papers
Op-Eds
Glossary of Abbreviations
Policy-relevant Articles Given RSIS Award
RSIS Publications for the Year
External Publications for the Year
Media
Cohesive Societies
Sustainable Security
Other Resource Pages
News Releases
Speeches
Video/Audio Channel
External Podcasts
Events
Contact Us
S. Rajaratnam School of International Studies Think Tank and Graduate School Ponder The Improbable Since 1966
Nanyang Technological University Nanyang Technological University
  • About RSIS
      IntroductionBuilding the FoundationsWelcome MessageBoard of GovernorsHonours and Awards for RSIS Staff and StudentsRSIS Endowment FundEndowed ProfessorshipsCareer OpportunitiesGetting to RSIS
      Staff ProfilesExecutive Deputy Chairman’s OfficeDean’s OfficeManagementDistinguished FellowsFaculty and ResearchAssociate Research Fellows, Senior Analysts and Research AnalystsVisiting FellowsAdjunct FellowsAdministrative Staff
  • Research
      Research CentresCentre for Multilateralism Studies (CMS)Centre for Non-Traditional Security Studies (NTS Centre)Centre of Excellence for National SecurityInstitute of Defence and Strategic Studies (IDSS)International Centre for Political Violence and Terrorism Research (ICPVTR)
      Research ProgrammesNational Security Studies Programme (NSSP)Social Cohesion Research Programme (SCRP)Studies in Inter-Religious Relations in Plural Societies (SRP) Programme
      Other ResearchFuture Issues and Technology ClusterResearch@RSISScience and Technology Studies Programme (STSP) (2017-2020)
  • Graduate Education
      Graduate Programmes OfficeExchange Partners and ProgrammesHow to ApplyFinancial AssistanceMeet the Admissions Team: Information Sessions and other eventsRSIS Alumni
  • Outreach
      Global NetworksAbout Global NetworksRSIS Alumni
      Executive EducationAbout Executive EducationSRP Executive ProgrammeTerrorism Analyst Training Course (TATC)
      International ProgrammesAbout International ProgrammesAsia-Pacific Programme for Senior Military Officers (APPSMO)Asia-Pacific Programme for Senior National Security Officers (APPSNO)International Conference on Cohesive Societies (ICCS)International Strategy Forum-Asia (ISF-Asia)
  • Publications
      RSIS PublicationsAnnual ReviewsBooksBulletins and NewslettersRSIS Commentary SeriesCounter Terrorist Trends and AnalysesCommemorative / Event ReportsFuture IssuesIDSS PapersInterreligious RelationsMonographsNTS InsightPolicy ReportsWorking Papers
      External PublicationsAuthored BooksJournal ArticlesEdited BooksChapters in Edited BooksPolicy ReportsWorking PapersOp-Eds
      Glossary of AbbreviationsPolicy-relevant Articles Given RSIS AwardRSIS Publications for the YearExternal Publications for the Year
  • Media
      Cohesive SocietiesSustainable SecurityOther Resource PagesNews ReleasesSpeechesVideo/Audio ChannelExternal Podcasts
  • Events
  • Contact Us
    • Connect with Us

      rsis.ntu
      rsis_ntu
      rsisntu
      rsisvideocast
      school/rsis-ntu
      rsis.sg
      rsissg
      RSIS
      RSS
      Subscribe to RSIS Publications
      Subscribe to RSIS Events

      Getting to RSIS

      Nanyang Technological University
      Block S4, Level B3,
      50 Nanyang Avenue,
      Singapore 639798

      Click here for direction to RSIS

      Get in Touch

    Connect
    Search
    • RSIS
    • Publication
    • RSIS Publications
    • India’s Vaccine Ambition: How Far Can It Go?
    • Annual Reviews
    • Books
    • Bulletins and Newsletters
    • RSIS Commentary Series
    • Counter Terrorist Trends and Analyses
    • Commemorative / Event Reports
    • Future Issues
    • IDSS Papers
    • Interreligious Relations
    • Monographs
    • NTS Insight
    • Policy Reports
    • Working Papers

    India’s Vaccine Ambition: How Far Can It Go?
    P. S. Suryanarayana

    06 July 2021

    download pdf

    SYNOPSIS

    Battling the devastating second wave of COVID-19, India sought urgent help from the distant US even though China expressed neighbourly support. Delhi is seeking ‘vaccine partnership’ with the US and a new template of globalisation as an economic alternative to China’s dominance of supply chains. The unsettled China-India relationship also appears to influence Delhi’s thinking.

    Source: Unsplash

    COMMENTARY

    ON 12 JUNE 2021, India urged the Group of Seven (G7) industrialised countries to promote free trade in vaccine-related and other technologies being developed to fight the COVID-19 pandemic. At the World Trade Organisation (WTO), India and South Africa had earlier proposed a waiver of the relevant intellectual property rights (IPR).

    Such an IPR waiver might enable competent countries to produce qualitative COVID-19 vaccines, enlarging the global base for COVID-19 relief. This could arguably be the first step towards a new globalisation template. Following a US-led tele-conference among seven Indo-Pacific countries in May 2020, India had said all those seven states “underlined the need for a new template of globalisation” to overcome COVID-19.

    Why the Push for a New Globalisation Template

    The crux of the reported Indo-Pacific consensus in 2020 calling for a new globalisation template was to reduce the world’s reliance on the perceived Chinese monopoly over numerous industrial and other supply chains. Delhi therefore expects the US to become a source of critical help to roll back the pandemic’s second wave in India in 2021.

    Indian External Affairs Minister S. Jaishankar visited Washington in May 2021, seeking to forge a US-India vaccine partnership. Responding on 3 June, America announced that it would supply its COVID-19 vaccines to India under President Joe Biden’s “Strategy for Global Vaccine Sharing”.

    China responded by matching this. The Chinese ambassador to India, Sun Weidong portrayed on 8 June how his country was second to none in helping India fight the pandemic. Tapping the Chinese economy for this purpose “fully shows that the industrial and supply chains with China’s participation are highly effective and reliable”, he emphasised.

    Sun’s apparent aim was to counter the idea of a multi-national network of resilient supply chains as an alternative to those already radiating from China. But, in India’s view, the real issue is the lack of political trust when it comes to China, given Beijing’s growing control over a wide range of supply chains.

    Delicate Situation

    In light of Delhi’s concerns, Chinese President Xi Jinping messaged Indian Prime Minister Narendra Modi on 30 April that the “human race belongs to a community with a shared future”. On that basis Xi offered Modi “support and help” to fight the pandemic’s second wave.

    Xi’s intention was to show that his offer was not a cosmetic conciliatory gesture amidst the ongoing Sino-Indian military standoff. Xi made the offer despite Beijing’s “concern and regret” over the recent exclusion of Chinese telecom majors from India’s trials for its rollout of 5G knowhow and equipment.

    Chinese Foreign Minister Wang Yi telephoned his Indian counterpart Jaishankar to detail the help being offered to battle COVID-19. When Jaishankar raised the concerns of Indian entities which were already buying COVID-19 relief materials from China, Wang Yi assured “facilitation” of customs clearances and shipping logistics.

    However, with the unresolved year-long military crisis overshadowing, the pricing for Indian purchases of Chinese COVID-19 relief materials took on contentious overtones. Delhi began evaluating the risks of its over-dependence on China.

    By mid-May, Beijing’s response was that the pricing was determined by market forces and China itself had to pay high prices while fighting COVID-19 in its initial stage. For good measure, Beijing emphasised the Chinese supplies of essential raw materials for vaccine production in India over time.

    A Pharma Factory of the World?

    India is a key pharmaceutical factory of the world, including as a producer of generic vaccines. But the scale of China’s current production of COVID-19 vaccines is a new factor of relevance to India in the global pharmaceutical sector. Competitively, India has begun to seek assured supplies of raw materials from the US for the production of COVID-19 vaccines for domestic and global use.

    Some of these raw materials can be used in both civil and military sectors, making it a sensitive matter. This was evident in the Pentagon’s brief non-committal statement on US Defence Secretary Lloyd Austin’s talks with Jaishankar in May. They “discussed opportunities to deepen coordination amid the resurgence of COVID-19 cases [in India]”. No details were given.

    But Delhi needs a sustained supply of US-origin raw materials for COVID-19 vaccine production because Indian requirements to fight the pandemic have soared. Furthermore, severely affected internationally is Modi’s “Vaccine Maitri” (vaccine-borne friendship) programme of humanitarian and commercial exports.

    Indo-Pacific Hub for Vaccine Production?

    Already identified as a potential Indo-Pacific hub for COVID-19 vaccine production, India’s hope of becoming an exemplary major power depends on this niche role among other factors. On 12 March, the role was assigned to India at an online summit of the Quad – a security forum comprising the US, Japan, India and Australia.

    Under the plan, qualitative COVID-19 vaccine, based on American technologies, would be manufactured in India. Financial resources for the production and distribution in the Indo-Pacific region were also identified.

    For the Quad initiative to become fully operational, a substantive US-India vaccine partnership and a waiver of the relevant IPR would be essential. Separately, India seeks to compete with China, two of whose COVID-19 vaccines have received emergency-use listing by the World Health Organisation (WHO). A made-by-India COVID-19 vaccine is said to be awaiting WHO’s approval.

    On balance, while accepting support from the increasingly Sino-sceptic US and G7, India runs the risk of a recessed dream of becoming a global player by its own efforts. It should control and roll back the COVID-19 pandemic in the country and stabilise relations with China to stay relevant to the wider world.

    About the Author

    P S Suryanarayana is an Adjunct Senior Fellow with the S. Rajaratnam School of International Studies (RSIS), Nanyang Technological University (NTU), Singapore. He is author of ‘The Elusive Tipping Point: China-India Ties for a New Order’ (Singapore, World Scientific, 2021). This is part of a series.

    Categories: RSIS Commentary Series / Country and Region Studies / Non-Traditional Security / East Asia and Asia Pacific / South Asia / Southeast Asia and ASEAN / Global
    comments powered by Disqus

    SYNOPSIS

    Battling the devastating second wave of COVID-19, India sought urgent help from the distant US even though China expressed neighbourly support. Delhi is seeking ‘vaccine partnership’ with the US and a new template of globalisation as an economic alternative to China’s dominance of supply chains. The unsettled China-India relationship also appears to influence Delhi’s thinking.

    Source: Unsplash

    COMMENTARY

    ON 12 JUNE 2021, India urged the Group of Seven (G7) industrialised countries to promote free trade in vaccine-related and other technologies being developed to fight the COVID-19 pandemic. At the World Trade Organisation (WTO), India and South Africa had earlier proposed a waiver of the relevant intellectual property rights (IPR).

    Such an IPR waiver might enable competent countries to produce qualitative COVID-19 vaccines, enlarging the global base for COVID-19 relief. This could arguably be the first step towards a new globalisation template. Following a US-led tele-conference among seven Indo-Pacific countries in May 2020, India had said all those seven states “underlined the need for a new template of globalisation” to overcome COVID-19.

    Why the Push for a New Globalisation Template

    The crux of the reported Indo-Pacific consensus in 2020 calling for a new globalisation template was to reduce the world’s reliance on the perceived Chinese monopoly over numerous industrial and other supply chains. Delhi therefore expects the US to become a source of critical help to roll back the pandemic’s second wave in India in 2021.

    Indian External Affairs Minister S. Jaishankar visited Washington in May 2021, seeking to forge a US-India vaccine partnership. Responding on 3 June, America announced that it would supply its COVID-19 vaccines to India under President Joe Biden’s “Strategy for Global Vaccine Sharing”.

    China responded by matching this. The Chinese ambassador to India, Sun Weidong portrayed on 8 June how his country was second to none in helping India fight the pandemic. Tapping the Chinese economy for this purpose “fully shows that the industrial and supply chains with China’s participation are highly effective and reliable”, he emphasised.

    Sun’s apparent aim was to counter the idea of a multi-national network of resilient supply chains as an alternative to those already radiating from China. But, in India’s view, the real issue is the lack of political trust when it comes to China, given Beijing’s growing control over a wide range of supply chains.

    Delicate Situation

    In light of Delhi’s concerns, Chinese President Xi Jinping messaged Indian Prime Minister Narendra Modi on 30 April that the “human race belongs to a community with a shared future”. On that basis Xi offered Modi “support and help” to fight the pandemic’s second wave.

    Xi’s intention was to show that his offer was not a cosmetic conciliatory gesture amidst the ongoing Sino-Indian military standoff. Xi made the offer despite Beijing’s “concern and regret” over the recent exclusion of Chinese telecom majors from India’s trials for its rollout of 5G knowhow and equipment.

    Chinese Foreign Minister Wang Yi telephoned his Indian counterpart Jaishankar to detail the help being offered to battle COVID-19. When Jaishankar raised the concerns of Indian entities which were already buying COVID-19 relief materials from China, Wang Yi assured “facilitation” of customs clearances and shipping logistics.

    However, with the unresolved year-long military crisis overshadowing, the pricing for Indian purchases of Chinese COVID-19 relief materials took on contentious overtones. Delhi began evaluating the risks of its over-dependence on China.

    By mid-May, Beijing’s response was that the pricing was determined by market forces and China itself had to pay high prices while fighting COVID-19 in its initial stage. For good measure, Beijing emphasised the Chinese supplies of essential raw materials for vaccine production in India over time.

    A Pharma Factory of the World?

    India is a key pharmaceutical factory of the world, including as a producer of generic vaccines. But the scale of China’s current production of COVID-19 vaccines is a new factor of relevance to India in the global pharmaceutical sector. Competitively, India has begun to seek assured supplies of raw materials from the US for the production of COVID-19 vaccines for domestic and global use.

    Some of these raw materials can be used in both civil and military sectors, making it a sensitive matter. This was evident in the Pentagon’s brief non-committal statement on US Defence Secretary Lloyd Austin’s talks with Jaishankar in May. They “discussed opportunities to deepen coordination amid the resurgence of COVID-19 cases [in India]”. No details were given.

    But Delhi needs a sustained supply of US-origin raw materials for COVID-19 vaccine production because Indian requirements to fight the pandemic have soared. Furthermore, severely affected internationally is Modi’s “Vaccine Maitri” (vaccine-borne friendship) programme of humanitarian and commercial exports.

    Indo-Pacific Hub for Vaccine Production?

    Already identified as a potential Indo-Pacific hub for COVID-19 vaccine production, India’s hope of becoming an exemplary major power depends on this niche role among other factors. On 12 March, the role was assigned to India at an online summit of the Quad – a security forum comprising the US, Japan, India and Australia.

    Under the plan, qualitative COVID-19 vaccine, based on American technologies, would be manufactured in India. Financial resources for the production and distribution in the Indo-Pacific region were also identified.

    For the Quad initiative to become fully operational, a substantive US-India vaccine partnership and a waiver of the relevant IPR would be essential. Separately, India seeks to compete with China, two of whose COVID-19 vaccines have received emergency-use listing by the World Health Organisation (WHO). A made-by-India COVID-19 vaccine is said to be awaiting WHO’s approval.

    On balance, while accepting support from the increasingly Sino-sceptic US and G7, India runs the risk of a recessed dream of becoming a global player by its own efforts. It should control and roll back the COVID-19 pandemic in the country and stabilise relations with China to stay relevant to the wider world.

    About the Author

    P S Suryanarayana is an Adjunct Senior Fellow with the S. Rajaratnam School of International Studies (RSIS), Nanyang Technological University (NTU), Singapore. He is author of ‘The Elusive Tipping Point: China-India Ties for a New Order’ (Singapore, World Scientific, 2021). This is part of a series.

    Categories: RSIS Commentary Series / Country and Region Studies / Non-Traditional Security

    Popular Links

    About RSISResearch ProgrammesGraduate EducationPublicationsEventsAdmissionsCareersVideo/Audio ChannelRSIS Intranet

    Connect with Us

    rsis.ntu
    rsis_ntu
    rsisntu
    rsisvideocast
    school/rsis-ntu
    rsis.sg
    rsissg
    RSIS
    RSS
    Subscribe to RSIS Publications
    Subscribe to RSIS Events

    Getting to RSIS

    Nanyang Technological University
    Block S4, Level B3,
    50 Nanyang Avenue,
    Singapore 639798

    Click here for direction to RSIS

    Get in Touch

      Copyright © S. Rajaratnam School of International Studies. All rights reserved.
      Privacy Statement / Terms of Use
      Help us improve

        Rate your experience with this website
        123456
        Not satisfiedVery satisfied
        What did you like?
        0/255 characters
        What can be improved?
        0/255 characters
        Your email
        Please enter a valid email.
        Thank you for your feedback.
        This site uses cookies to offer you a better browsing experience. By continuing, you are agreeing to the use of cookies on your device as described in our privacy policy. Learn more
        OK
        Latest Book
        more info